GHK-Cu and skin claims: what the evidence supports

A recent TikTok video by creator Aian uses the caption “Type 1 to get catalog” and tags like #peptide and #greymarket to draw viewers into a direct-message funnel. The implied claim is that GHK-Cu, a copper peptide, is a powerful skin-repair and anti-aging compound, and that viewers should obtain a catalog to purchase it. While GHK-Cu is indeed a researched peptide, the social clip lacks nuance and context, potentially overstating its benefits and ignoring regulatory and safety considerations.

What the clip is claiming

The clip does not provide a detailed explanation; it relies on hashtags and the promise of a catalog to generate interest. The underlying message is that GHK-Cu is a “must-have” peptide for skin health, with implied benefits such as wrinkle reduction, improved elasticity, and accelerated wound healing. The urgency of “Type 1 to get catalog” suggests scarcity and exclusivity, which are common in grey-market peptide promotions.

What the research neighborhood actually covers

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide that binds copper ions. Research, primarily from the 1980s to 2000s, has investigated its roles in wound healing, tissue remodeling, and anti-aging. Studies have shown that GHK-Cu can stimulate collagen synthesis, promote angiogenesis, and act as an antioxidant. In vitro and some animal studies support these effects, and topical formulations have been used in cosmetics for decades. However, high-quality human clinical trials are limited, and most evidence comes from cell cultures or small studies.

Limits, missing context, and what a 15-second clip cannot show

A short TikTok clip cannot convey the complexity of peptide research. For GHK-Cu, key missing context includes: the difference between topical and systemic use, the importance of copper balance (excess copper can be toxic), the lack of standardized dosing, and the fact that many studies are industry-funded or use proprietary formulations. Additionally, the clip does not mention that GHK-Cu is not approved by regulatory agencies for cosmetic or therapeutic claims in most countries, and that grey-market products are not subject to quality control. The clip also ignores potential side effects like skin irritation or allergic reactions.

How this maps to named research compounds

GHK-Cu is the primary compound in question. It is available in research catalogs, including our own, but only for laboratory and research purposes. There is no clinical evidence to support self-administration for skin conditions. Other peptides in our catalog, such as BPC-157 or TB-500, are sometimes mentioned in similar social media contexts for tissue repair, but they are not the focus of this clip. We do not endorse any off-label use.

Research-use caveat

All peptides listed in our catalog are intended for research use only (RUO). They are not approved for human or animal consumption, diagnosis, or treatment. Researchers must handle these compounds with appropriate safety protocols and comply with all applicable laws. The information provided here is for educational purposes and does not constitute medical advice.